Literature DB >> 9748559

Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor.

H R Arias1.   

Abstract

The nicotinic acetylcholine receptor (AChR) is the paradigm of the neurotransmitter-gated ion channel superfamily. The pharmacological behavior of the AChR can be described as three basic processes that progress sequentially. First, the neurotransmitter acetylcholine (ACh) binds the receptor. Next, the intrinsically coupled ion channel opens upon ACh binding with subsequent ion flux activity. Finally, the AChR becomes desensitized, a process where the ion channel becomes closed in the prolonged presence of ACh. The existing equilibrium among these physiologically relevant processes can be perturbed by the pharmacological action of different drugs. In particular, non-competitive inhibitors (NCIs) inhibit the ion flux and enhance the desensitization rate of the AChR. The action of NCIs was studied using several drugs of exogenous origin. These include compounds such as chlorpromazine (CPZ), triphenylmethylphosphonium (TPMP+), the local anesthetics QX-222 and meproadifen, trifluoromethyl-iodophenyldiazirine (TID), phencyclidine (PCP), histrionicotoxin (HTX), quinacrine, and ethidium. In order to understand the mechanism by which NCIs exert their pharmacological properties several laboratories have studied the structural characteristics of their binding sites, including their respective locations on the receptor. One of the main objectives of this review is to discuss all available experimental evidence regarding the specific localization of the binding sites for exogenous NCIs. For example, it is known that the so-called luminal NCIs bind to a series of ring-forming amino acids in the ion channel. Particularly CPZ, TPMP+, QX-222, cembranoids, and PCP bind to the serine, the threonine, and the leucine ring, whereas TID and meproadifen bind to the valine and extracellular rings, respectively. On the other hand, quinacrine and ethidium, termed non-luminal NCIs, bind to sites outside the channel lumen. Specifically, quinacrine binds to a non-annular lipid domain located approximately 7 A from the lipid-water interface and ethidium binds to the vestibule of the AChR in a site located approximately 46 A away from the membrane surface and equidistant from both ACh binding sites. The non-annular lipid domain has been suggested to be located at the intermolecular interfaces of the five AChR subunits and/or at the interstices of the four (M1-M4) transmembrane domains. One of the most important concepts in neurochemistry is that receptor proteins can be modulated by endogenous substances other than their specific agonists. Among membrane-embedded receptors, the AChR is one of the best examples of this behavior. In this regard, the AChR is non-competitively modulated by diverse molecules such as lipids (fatty acids and steroids), the neuropeptide substance P, and the neurotransmitter 5-hydroxytryptamine (5-HT). It is important to take into account that the above mentioned modulation is produced through a direct binding of these endogenous molecules to the AChR. Since this is a physiologically relevant issue, it is useful to elucidate the structural components of the binding site for each endogenous NCI. In this regard, another important aim of this work is to review all available information related to the specific localization of the binding sites for endogenous NCIs. For example, it is known that both neurotransmitters substance P and 5-HT bind to the lumen of the ion channel. Particularly, the locus for substance P is found in the deltaM2 domain, whereas the binding site for 5-HT and related compounds is putatively located on both the serine and the threonine ring. Instead, fatty acid and steroid molecules bind to non-luminal sites. More specifically, fatty acids may bind to the belt surrounding the intramembranous perimeter of the AChR, namely the annular lipid domain, and/or to the high-affinity quinacrine site which is located at a non-annular lipid domain. Additionally, steroids may bind to a site located on the extracellular hydrophi

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748559     DOI: 10.1016/s0304-4157(98)00004-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801.

Authors:  G P Hess; H Ulrich; H G Breitinger; L Niu; A M Gameiro; C Grewer; S Srivastava; J E Ippolito; S M Lee; V Jayaraman; S E Coombs
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Conformation-dependent hydrophobic photolabeling of the nicotinic receptor: electrophysiology-coordinated photochemistry and mass spectrometry.

Authors:  John F Leite; Michael P Blanton; Mona Shahgholi; Dennis A Dougherty; Henry A Lester
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

3.  Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Ryan E Pavlovicz; Jerad D Allen; Tatiana F González-Cestari; Crina M Orac; Andrew B Bonnell; Michael X Zhu; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

Review 4.  Activation of the Macrophage α7 Nicotinic Acetylcholine Receptor and Control of Inflammation.

Authors:  Carlos A Báez-Pagán; Manuel Delgado-Vélez; José A Lasalde-Dominicci
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-14       Impact factor: 4.147

5.  Non-competitive inhibitory activities of morphinan and morphine derivatives at the alpha 3 beta 4 Neuronal nicotinic acetylcholine receptor determined using nonlinear chromatography and chemometric techniques.

Authors:  Krzysztof Jozwiak; Ruin Moaddel; Rika Yamaguchi; Alexandre Maciuk; Irving W Wainer
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

6.  Allosteric binding site in a Cys-loop receptor ligand-binding domain unveiled in the crystal structure of ELIC in complex with chlorpromazine.

Authors:  Mieke Nys; Eveline Wijckmans; Ana Farinha; Özge Yoluk; Magnus Andersson; Marijke Brams; Radovan Spurny; Steve Peigneur; Jan Tytgat; Erik Lindahl; Chris Ulens
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

7.  Desensitization mechanism in prokaryotic ligand-gated ion channel.

Authors:  Phanindra Velisetty; Sudha Chakrapani
Journal:  J Biol Chem       Date:  2012-04-03       Impact factor: 5.157

8.  Modeling of the pore domain of the GLUR1 channel: homology with K+ channel and binding of channel blockers.

Authors:  Denis B Tikhonov; Jan R Mellor; Peter N R Usherwood; Lev G Magazanik
Journal:  Biophys J       Date:  2002-04       Impact factor: 4.033

9.  Chloride channels of glycine and GABA receptors with blockers: Monte Carlo minimization and structure-activity relationships.

Authors:  B S Zhorov; P D Bregestovski
Journal:  Biophys J       Date:  2000-04       Impact factor: 4.033

Review 10.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.